Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Open access
Landi, Lorenza, D’Incà, Federica, Gelibter, Alain, Chiari, Rita, Grossi, Francesco, Delmonte, Angelo, Passaro, Antonio, Signorelli, Diego, Gelsomino, Francesco, Galetta, Domenico, Giannarelli, Diana, Soto Parra, Hector, Minuti, Gabriele, Tiseo, Marcello, Migliorino, Maria Rita, Cognetti, Francesco, Toschi, Luca, Bidoli, Paolo, Piantedosi, Francovito, Calabro’, Luana, Cappuzzo, Federico · 2019 · Journal for ImmunoTherapy of Cancer

Abstract

BACKGROUND: Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. METHODS: Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM. RESULTS: Cohort A accounted for 1588 patients with non-squamous NSCLC, including 626 (39%) with (BoM+) and 962 (61%) without BoM (BoM-). Cohort B accounted for 371 patients with squamous histology including 120 BoM+ (32%) and 251 (68%) BoM- cases. BoM+ had lower overall response rate (ORR; Cohort A: 12% versus 23%, p < 0.0001; Cohort B: 13% versus 22%, p = 0.04), shorter progression free survival (PFS; Cohort A: 3.0 versus 4.0 months, p < 0.0001; Cohort B: 2.7 versus 5.2 months, p < 0.0001) and overall survival (OS; Cohort A: 7.4 versus 15.3 months, p < 0.0001; Cohort B: 5.0 versus 10.9 months, p < 0.0001). Moreover, BoM negatively affected outcome irrespective of performance status (PS; OS in both cohorts: p < 0.0001) and liver metastases (OS cohort A: p < 0.0001; OS Cohort B: p = 0.48). At multivariate analysis, BoM independently associated with higher risk of death (cohort A: HR 1.50; cohort B: HR 1.78). CONCLUSIONS: BoM impairs immunotherapy efficacy. Accurate bone staging should be included in clinical trials with immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-019-0793-8

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 167

Metadata

Authors
Landi, L., D’Incà, F., Gelibter, A., Chiari, R., Grossi, F., Delmonte, A., Passaro, A., Signorelli, D., Gelsomino, F., Galetta, D., Giannarelli, D., Soto Parra, H., Minuti, G., Tiseo, M., Migliorino, M. R., Cognetti, F., Toschi, L., Bidoli, P., Piantedosi, F., Calabro’, L., & Cappuzzo, F.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2019-11-21
Volume
7
Issue
1
Pages
316-316
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2990769829
Cited by
167
References
9
FWCI
7.53
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. https://app.cochat.ai/papers/10.1186/s40425-019-0793-8
The paper
Landi, L., D’Incà, F., Gelibter, A., Chiari, R., Grossi, F., Delmonte, A., Passaro, A., Signorelli, D., Gelsomino, F., Galetta, D., Giannarelli, D., Soto Parra, H., Minuti, G., Tiseo, M., Migliorino, M. R., Cognetti, F., Toschi, L., Bidoli, P., Piantedosi, F., . . . Cappuzzo, F. (2019). Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-019-0793-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.